Article

Alcon unveils thermal pulsation system for meibomian gland disfunction

The company’s Systane iLux2 Meibomian Gland Dysfunction Thermal Pulsation System is a handheld device that allows patients to see the need for treatment and visualize their procedure.

Alcon this week unveiled its Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.

According to the company, with new imaging technology to capture infrared photos and HD video of the meibomian glands, this all-in-one handheld device allows patients to see the need for treatment and visualize their procedure, and experience results in as little as one week.1

“Alcon is dedicated to the advancement of medical device technology and providing Eye Care Professionals (ECPs) with the tools needed to effectively treat their patients,” Fred Ellis, vice president of US Pharmaceutical and Dry Eye, Alcon, said in a statement. “With the Systane iLux2 MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.”

The company pointed out that the Systane iLux2 MGD Thermal Pulsation System expands Alcon’s current dry eye treatment offerings and allows practitioners to tailor MGD treatment to the needs of each of their patients in 8 to 12 minutes.1,2

  • The device’s imaging technology allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure.
  • ECPs can customize heat and compression across each easy-to-visualize treatment zone.

According to Alcon, Systane iLux2 MGD Thermal Pulsation System can help Eye Care Practitioners build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images.

Eric D. Donnenfeld, MD, FAAO, Ophthalmic Consultants of Long Island, NY, pointed out that 56% of MGD patients see 4 or more eye care practitioners in search of proper diagnosis and relief.3

This is a prevalent diagnosis in my practice, and it is essential for me to stay on top of the latest treatment options,”Donnenfeld said in a statement. “The new Systane iLux2 MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients’ needs and help them see, understand and value their MGD treatment.”

References
1. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLux and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clin Ophthalmol. 2020;14:405-418.
2. Alcon data on file, 2019.
3. The Dry Eye Problem. Building Your Dry Eye Center of Excellence. Review of Optometric Business supplement. https://www.reviewob.com/building-your-dry-eye-center-of-excellence/. Accessed April 4, 2022.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.